Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
News|Articles|February 13, 2019
Daurismo for Newly Diagnosed AML
Author(s)Drew Boxler
Advertisement
Daurismo (glasdegib, Pfizer)
Indications: Newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older and have comorbidities that preclude use of intensive induction chemotherapy
Dosage: 100 mg orally, once daily.
Contraindications: None
Advertisement
Related to this article
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
Advertisement
Advertisement
Trending on Drug Topics
1
CagriSema Reduces Weight in Women Across Menopause Stages, HT Use
2
Pharmacist Roles, Risks in Guiding AI-Enabled Medical Device Use
3
EloraTZP Shows Greater Weight Loss, A1C Reduction Than Tirzepatide
4
White House Declares Increased Focus on Women’s Health in US
5